Welcome to our dedicated page for BioSig Technologies news (Ticker: BSGM), a resource for investors and traders seeking the latest updates and insights on BioSig Technologies stock.
BioSig Technologies, Inc. (Nasdaq: BSGM) is a Minneapolis-based medical technology company focused on the development and commercialization of advanced digital signal processing technology. The company aims to revolutionize the $3 billion electrophysiology (EP) market with its flagship product, the PURE EP™ Platform. This FDA-cleared, non-invasive class II device combines innovative hardware and software to provide unparalleled clarity and precision in visualizing intracardiac signals. The technology facilitates highly targeted cardiac ablation procedures, improving procedural efficiency and patient outcomes.
BioSig's commitment to addressing healthcare's critical priorities—saving time, reducing costs, and saving lives—is reflected in its collaborative efforts with leading medical centers, including the Cleveland Clinic, Mayo Clinic, and Texas Cardiac Arrhythmia Institute. The PURE EP™ Platform's Near-Field Tracking (NFT) algorithm, introduced in Q4 2023, has already demonstrated a significant reduction in ablation time by approximately 66%, highlighting its potential to enhance clinical procedures.
Despite recent challenges, including workforce reductions and strategic shifts, BioSig remains focused on expanding its product's adoption and exploring new market opportunities. The company recently appointed Bridge Associates International Pharmaceutical Consulting (BAIPC) to advise on business model strategies and continues to work on potential commercialization opportunities within the AI space.
Under the leadership of a new CEO and a reconstituted Board of Directors, BioSig is committed to restoring and creating lasting shareholder value. The company has also addressed compliance issues with the Nasdaq Hearings Panel, further solidifying its position in the marketplace.
For more information and the latest updates, visit the SEC's website.
BioSig Technologies (Nasdaq: BSGM) announced a conference call scheduled for December 21, 2021, at 2 PM ET to discuss its innovative signal processing platform aimed at improving ECG and intra-cardiac signal fidelity. The call will be accessible via U.S. toll-free and international numbers. The PURE EP (tm) System, BioSig's FDA-cleared device, has shown a 75% improvement in signal quality in clinical studies. With increasing cases of atrial fibrillation, the company aims to enhance cardiac care efficiency. A webcast replay will be available following the call.
BioSig Technologies, Inc. (Nasdaq: BSGM) announced that Executive Vice President Natasha Drapeau will present at the Benzinga All Access event on December 14, 2021, at 9:40 am EST. The company has seen solid performance with the first commercial sales of its PURE EP™ System, completing approximately 1800 patient cases. The device aims to enhance cardiac signal quality, with clinical data showing a 75% improvement over conventional sources. Atrial fibrillation affects millions and incurs significant healthcare costs, highlighting the demand for innovative solutions.
BioSig Technologies has appointed Gray Fleming as Chief Commercial Officer to enhance its market presence in electrophysiology. With over 20 years of healthcare experience, including leadership roles at Abbott Laboratories, Fleming aims to leverage his expertise to boost sales and market share of the PURE EP™ System, a non-invasive device designed for cardiac procedures. The company reports positive clinical data, showing a 75% improvement in signal quality. BioSig is currently focused on launching the PURE EP™ in key U.S. markets, including the Northeast, Texas, and Florida.
BioSig Technologies, Inc. (Nasdaq: BSGM) announced its participation in The Benchmark Company 10th Annual Discovery One on One Investor Conference on December 2, 2021. The company's leadership will update investors on the rollout of their FDA-cleared PURE EP™ System, which enhances procedural efficiency in cardiac electrophysiology. Over 1700 patient cases have been completed by 73 physicians using this system. The event will also discuss results from a recent clinical trial during a roundtable on November 18, 2021.
BioSig Technologies (NASDAQ: BSGM) announced a partnership with the Technion Research & Development Foundation for AI-driven research on atrial fibrillation procedures. The feasibility study will utilize data from BioSig's PURE EP(tm) System to develop predictive algorithms for arrhythmia care. Atrial fibrillation affects over 33 million globally, with significant healthcare costs. BioSig's technology aims to enhance procedural efficiency in cardiac electrophysiology, with ongoing clinical data supporting its effectiveness.
BioSig Technologies (Nasdaq: BSGM) will host a live roundtable webinar on November 18, 2021, discussing results from the PURE EP 2.0 study recently published in the Journal of Cardiovascular Electrophysiology. The event, titled “PURE EP 2.0 Study Results: From Clinical Data to Clinical Applications,” will feature experts Andrea Natale, Amin Al-Ahmad, and Wendy Tzou, who will review the impact of high-fidelity signals on cardiac ablation procedures. The study reported a 75% improvement in intracardiac signal quality and a 93% consensus among blinded reviewers.
BioSig Technologies has announced the installation of its PURE EP™ System at the highly-ranked Medical City Heart Hospital in Dallas, TX, marking its 17th installation and fifth in Texas. The facility focuses on advanced cardiovascular care, making it an ideal site for the technology aimed at improving ECG signal fidelity. Over 71 physicians have already utilized the system in over 1600 patient cases. A recent multi-center study published in the Journal of Cardiovascular Electrophysiology showed a 75% improvement in signal quality using the PURE EP™ System.
BioSig Technologies announces the installation of a PURE EP™ System at Beth Israel Deaconess Medical Center, increasing its installed centers to 16. The evaluation is expected to begin in December 2021. To date, over 71 physicians have conducted more than 1,600 cases with the system, indicating growing adoption. Clinical data shows a 75% improvement in intracardiac signal quality. With 33 million people affected by atrial fibrillation globally, BioSig aims to capitalize on this significant market through its innovative technology.
BioSig Technologies (Nasdaq: BSGM) announced a new installation agreement for its PURE EP(tm) System at Methodist Hospital in San Antonio, TX, enhancing its presence in the key Texas market. This agreement marks the Company’s 15th installed center, with Methodist Hospital being a high-volume provider of cardiac ablation procedures. The PURE EP(tm) System has shown significant clinical benefits, including a 75% improvement in signal quality according to recent studies. The Company continues to focus on expanding its technology across strategic regions in the Northeast, Texas, and Florida.
BioSig Technologies, Inc. (NASDAQ: BSGM) reported significant growth in the adoption of its PURE EP™ System for arrhythmia care, surpassing its target with over 1,560 patient cases recorded as of October 21, 2021. This marks an increase from 1,000 cases in June 2021. The company anticipates completing between 1,700 and 1,800 procedures by year-end, boosted by declining COVID-19 hospitalization rates. Clinical research published in the Journal of Cardiovascular Electrophysiology indicated a 75% improvement in intracardiac signal quality, showcasing the technology's clinical value.
FAQ
What is the current stock price of BioSig Technologies (BSGM)?
What is the market cap of BioSig Technologies (BSGM)?
What does BioSig Technologies, Inc. do?
What is the PURE EP™ Platform?
Who are BioSig's collaborators?
What recent achievements has BioSig made?
How is BioSig addressing its financial and operational challenges?
What are BioSig's future plans?
How does the NFT algorithm benefit clinical procedures?
Is BioSig publicly traded?
What steps has BioSig taken to comply with Nasdaq requirements?
Where can I find more information about BioSig?
